Evidence map›Paper›PMID 39229011›Full record

ArticlebioRxiv : the preprint server for biology2024

Vaccines combining slow delivery and follicle targeting of antigens increase germinal center B cell clonal diversity and clonal expansion.

Kristen A Rodrigues, Yiming J Zhang, Aereas Aung, Duncan M Morgan, Laura Maiorino, Parisa Yousefpour, Grace Gibson, Gabriel Ozorowski, Justin R Gregory, Parastoo Amlashi and 5 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Kristen A RodriguesKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Cambridge, MA 02139 USA.ORCID 0000-0002-0680-9834
Yiming J ZhangKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Cambridge, MA 02139 USA.ORCID 0000-0002-8102-3815
Aereas AungKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Cambridge, MA 02139 USA.
Duncan M MorganKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Cambridge, MA 02139 USA.
Laura MaiorinoKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Cambridge, MA 02139 USA.
Parisa YousefpourKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Cambridge, MA 02139 USA.
Grace GibsonDepartment of Integrative, Structural and Computational Biology, The Scripps Research Institute; La Jolla, CA 92037 USA.
Gabriel OzorowskiDepartment of Integrative, Structural and Computational Biology, The Scripps Research Institute; La Jolla, CA 92037 USA.
Justin R GregoryKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Cambridge, MA 02139 USA.
Parastoo AmlashiKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Cambridge, MA 02139 USA.
Maureen BuckleyKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Cambridge, MA 02139 USA.
Andrew B WardConsortium for HIV/AIDS Vaccine Development, The Scripps Research Institute; La Jolla, CA 92037 USA.
William R SchiefRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University; Cambridge, MA 02139 USA.
J Christopher LoveKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Cambridge, MA 02139 USA.
Darrell J IrvineKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Cambridge, MA 02139 USA.ORCID 0000-0002-8637-1405

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
Virology and ImmunologyP01AI048240 · NIAID · UNIVERSITY OF WASHINGTON · PI RUPRECHT, RUTH MARGRIT · 2000 to 2020
$46.7M
Maximizing germinal centers and somatic hypermutation to HIV Env immunogensR37AI125068 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Shane P Crotty, Darrell J Irvine · 2021 to 2026
$5.4M
Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodiesR61AI161818 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ANDRABI, RAIEES AHMAD, SHAW, GEORGE M · 2021 to 2023
$4.7M
Maximizing germinal centers and somatic hypermutation to HIV Env immunogensR01AI125068 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROTTY, SHANE P, IRVINE, DARRELL J · 2016 to 2020
$4.3M
Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodiesR33AI161818 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ANDRABI, RAIEES AHMAD, SHAW, GEORGE M · 2024 to 2025
$3.2M
Immune engineering of optimized sequential immunization strategies for HIV vaccinesR33AI161297 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI CROTTY, SHANE P, IRVINE, DARRELL J · 2024 to 2025
$2.5M
Immune engineering of optimized sequential immunization strategies for HIV vaccinesR61AI161297 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI CROTTY, SHANE P, IRVINE, DARRELL J · 2021 to 2023
$2.3M
Controlling Vaccine Kinetics with Small Molecule DrugsF32AI164829 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YOUSEFPOUR, PARISA · 2022 to 2024
$184k
NCI NIH HHS P30 CA014051NIAID NIH HHS F32 AI164829NIAID NIH HHS P01 AI048240NIAID NIH HHS R01 AI125068NIAID NIH HHS R33 AI161297NIAID NIH HHS R33 AI161818NIAID NIH HHS R37 AI125068NIAID NIH HHS R61 AI161297NIAID NIH HHS R61 AI161818NIAID NIH HHS UM1 AI144462
6 · The paper itself

Abstract

Vaccines incorporating slow delivery, multivalent antigen display, or immunomodulation through adjuvants have an important role to play in shaping the humoral immune response. Here we analyzed mechanisms of action of a clinically relevant combination adjuvant strategy, where phosphoserine (pSer)-tagged immunogens bound to aluminum hydroxide (alum) adjuvant (promoting prolonged antigen delivery to draining lymph nodes) are combined with a potent saponin nanoparticle adjuvant termed SMNP (which alters lymph flow and antigen entry into lymph nodes). When employed with a stabilized HIV Env trimer antigen in mice, this combined adjuvant approach promoted substantial enhancements in germinal center (GC) and antibody responses relative to either adjuvant alone. Using scRNA-seq and scBCR-seq, we found that the alum-pSer/SMNP combination both increased the diversity of GC B cell clones and increased GC B cell clonal expansion, coincident with increases in the expression of

Identifiers

PMID39229011
PMCPMC11370361

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.